Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AGRX

AGRX - Agile Therapeutics Inc Stock Price, Fair Value and News

1.43USD-0.02 (-1.38%)Delayed

Market Summary

AGRX
USD1.43-0.02
Delayed
-1.38%

AGRX Stock Price

View Fullscreen

AGRX RSI Chart

AGRX Valuation

Market Cap

9.8M

Price/Earnings (Trailing)

-1.26

Price/Sales (Trailing)

0.46

EV/EBITDA

-3.64

Price/Free Cashflow

-0.93

AGRX Price/Sales (Trailing)

AGRX Profitability

Operating Margin

59.74%

EBT Margin

-36.25%

Return on Equity

-124.48%

Return on Assets

-61.8%

Free Cashflow Yield

-108.02%

AGRX Fundamentals

AGRX Revenue

Revenue (TTM)

21.5M

Rev. Growth (Yr)

49.91%

Rev. Growth (Qtr)

58.14%

AGRX Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

123.82%

Earnings Growth (Qtr)

128.73%

Breaking Down AGRX Revenue

Last 30 days

320.6%

Last 90 days

276.3%

Trailing 12 Months

-52.6%

How does AGRX drawdown profile look like?

AGRX Financial Health

Current Ratio

0.56

Debt/Equity

2.63

Debt/Cashflow

-0.64

AGRX Investor Care

Shares Dilution (1Y)

593.27%

Diluted EPS (TTM)

-2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202421.5M000
202312.9M16.3M20.0M19.6M
20225.7M6.7M8.4M10.9M
20211.6M2.5M3.3M4.1M
2020000749.0K

Tracking the Latest Insider Buys and Sells of Agile Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 03, 2023
coiante scott m
acquired
-
-
20,000
chief financial officer
Jun 28, 2023
welsh amy
acquired
-
-
13,500
chief commercial officer
Jun 28, 2023
conway robert g
acquired
-
-
13,500
chief supply chain officer
Jun 28, 2023
korner paul
acquired
-
-
13,500
chief medical officer
Jun 28, 2023
gilmore geoffrey
acquired
-
-
20,216
chief administrative officer
Jun 28, 2023
altomari alfred
acquired
-
-
46,463
chief executive officer
Jun 08, 2023
torrente josephine
acquired
-
-
935
-
Jun 08, 2023
barbari sharon
acquired
-
-
935
-
Jun 08, 2023
fischer seth h. z.
acquired
-
-
935
-
Jun 08, 2023
hubbard john w
acquired
-
-
935
-

1–10 of 50

Which funds bought or sold AGRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
sold off
-100
-8.00
-
-%
May 15, 2024
STATE STREET CORP
sold off
-100
-21,144
-
-%
May 15, 2024
CITADEL ADVISORS LLC
sold off
-100
-37,532
-
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-88.00
-
-%
May 15, 2024
Royal Bank of Canada
sold off
-100
-2,000
-
-%
May 15, 2024
INVESTOR AB
unchanged
-
-2,824
596
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-210,600
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-6,388
-
-%
May 13, 2024
UBS Group AG
sold off
-100
-2,705
-
-%
May 13, 2024
RENAISSANCE TECHNOLOGIES LLC
sold off
-100
-115,000
-
-%

1–10 of 24

Are Funds Buying or Selling AGRX?

Are funds buying AGRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGRX
No. of Funds

Unveiling Agile Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 09, 2024
beryl capital management llc
9.9%
680,000
SC 13G
Jul 02, 2024
klein roger m.
9.0%
618,000
SC 13G
Feb 13, 2024
lind global fund ii lp
1.8%
44,750
SC 13G/A
Feb 06, 2024
intracoastal capital, llc
0.9%
23,961
SC 13G/A
Feb 14, 2023
perceptive advisors llc
0%
0
SC 13G/A
Feb 13, 2023
lind global fund ii lp
9.9%
4,459,759
SC 13G/A
Feb 08, 2023
intracoastal capital, llc
6.3%
2,730,000
SC 13G/A
Jul 12, 2022
lind global fund ii lp
9.9%
3,250,223
SC 13G
Jul 11, 2022
intracoastal capital, llc
9.99%
3,430,345
SC 13G
Feb 14, 2022
perceptive advisors llc
17.5%
21,294,485
SC 13G/A

Recent SEC filings of Agile Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 16, 2024
DEFA14A
DEFA14A
Jul 16, 2024
8-K/A
Current Report
Jul 15, 2024
8-K/A
Current Report
Jul 12, 2024
PREM14A
PREM14A
Jul 09, 2024
SC 13G
Major Ownership Report
Jul 02, 2024
SC 13G
Major Ownership Report
Jun 27, 2024
RW
RW
Jun 26, 2024
DEFA14A
DEFA14A
Jun 26, 2024
8-K
Current Report
Jun 14, 2024
S-1
Initial Public Offering

Peers (Alternatives to Agile Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.68
2.44
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Agile Therapeutics Inc News

Latest updates
Defense World17 Jul 202409:07 am
Investing.com3 months ago

Agile Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue58.1%5,716,0003,614,5006,662,0005,503,0003,813,0003,995,5003,002,0002,126,0001,761,0001,513,5001,287,0001,185,000116,000749,000
Cost Of Revenue-23.3%1,680,0002,191,0002,477,0002,307,0002,003,0001,653,0001,425,0002,231,0001,527,0005,701,0002,711,0001,145,0001,161,000-
Gross Profit183.5%4,036,0001,423,5004,185,0003,196,0001,810,0002,342,5001,577,000-105,000234,000-4,187,500-1,424,00040,000-1,045,000467,000
Operating Expenses24.1%6,793,0005,474,5008,185,0008,322,0008,518,0009,220,00020,285,00011,293,00015,807,00018,170,50014,350,00016,691,00015,177,00017,208,000
  S&GA Expenses-1.3%3,682,0003,729,0004,800,0004,570,0004,670,0006,845,5005,560,0007,411,00010,553,00013,004,5009,386,00011,977,0009,253,00010,673,500
  R&D Expenses816.7%495,00054,000705,000703,000763,000352,000788,000856,0001,257,0001,673,0001,593,000862,0002,123,0003,012,000
EBITDA Margin54.3%-0.30-0.66-0.61-1.02-1.31-2.36-4.79-7.59-10.97-15.87-19.09-25.49-35.27-
Interest Expenses-39.2%185,000304,500341,000372,000402,000432,0001,004,000823,000872,0001,000,000999,000993,000922,000904,000
Income Taxes----------4,675,000-----
Earnings Before Taxes128.7%1,284,000-4,468,500-799,000-3,809,000-5,390,000-3,930,000-5,930,000-5,168,000-15,060,000-19,530,000-16,772,000-17,637,000-17,128,000-17,620,000
EBT Margin50.9%-0.36-0.74-0.70-1.17-1.58-2.76-5.44-8.45-12.01-17.33-20.72-27.45-37.91-
Net Income128.7%1,284,000-4,468,500-799,000-3,809,000-5,390,000-3,930,000-5,930,000-5,168,000-10,385,000-19,530,000-16,772,000-17,637,000-17,128,000-17,620,000
Net Income Margin50.9%-0.36-0.74-0.70-1.17-1.58-2.33-4.88-7.75-11.19-17.33-20.72-27.45-37.91-
Free Cashflow-1539.5%-2,476,000172,000365,000-8,519,000-1,595,000-1,559,000-16,703,000-2,941,000-14,877,000-16,673,000-18,645,000-15,414,000-14,739,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets23.0%13.0010.0011.0013.0014.0014.0018.0033.0029.0039.0037.0052.0059.0073.0089.0010310950.0034.0025.0026.00
  Current Assets25.8%12.0010.0010.0012.0011.0011.0015.0018.0014.0024.0022.0037.0044.0057.0073.0089.0095.0035.0020.0011.0012.00
    Cash Equivalents2.3%3.003.003.003.004.005.006.0013.004.0019.0015.0026.0016.0014.0024.0039.0094.0034.0018.0011.0012.00
  Inventory36.9%4.003.002.003.002.001.002.002.003.001.003.003.002.00--------
  Net PPE-33.3%0.000.000.000.000.000.000.0012.0012.0012.0013.0013.0014.0014.0014.0014.0014.0014.0014.0014.0014.00
Liabilities-13.7%23.0027.0023.0025.0023.0020.0021.0030.0035.0035.0026.0028.0024.0024.0023.0022.0018.004.003.003.003.00
  Current Liabilities3.2%21.0021.0018.0015.0019.0013.0012.0029.0026.0029.0010.0012.009.007.007.006.003.004.002.002.001.00
  Long Term Debt-----------16.0016.0016.0016.0016.0016.0015.00----
    LT Debt, Current-100.0%-2.002.002.002.001.001.0013.0012.0017.00-----------
Shareholder's Equity-------6.002.003.004.0011.0025.0035.0049.0066.0081.0091.0046.0032.0027325.00
  Retained Earnings0.3%-421-423-418-417-414-408-404-398-393-383-364-346-329-312-295-279-268-260-254-249-246
  Additional Paid-In Capital1.2%412407406406405403402401388387374372364362361360359306286273271
Shares Outstanding131.3%7.003.002.002.001.001.001.00---0.000.00---------
Float----5.00---14.00---101---197---52.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-1539.5%-2,476172365-8,519-1,595-1,559-16,703-2,934-14,751-16,618-18,580-15,336-14,668-17,342-15,320-6,765-7,884-3,270-5,080-2,378-4,961
  Share Based Compensation-40.9%333563439481498524536669764866887843742711647839621415378479490
Cashflow From Investing---------7.00-126-55.004,93518,39516,1857,527-173-47,880-164-68.00---
Cashflow From Financing620.5%2,535-487-2786,8757786609,82112,225-52321,0812,2626,59548411521016667,49419,44712,8941,4048,670
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AGRX Income Statement

2024-03-31
Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statements of Operations and Comprehensive Income (Loss)  
Revenues, net$ 5,716$ 3,813
Cost of product revenues1,6802,003
Gross profit4,0361,810
Operating expenses:  
Research and development495763
Selling and marketing3,6824,670
General and administrative2,6163,085
Total operating expenses6,7938,518
Loss from operations(2,757)(6,708)
Other income (expense)  
Interest income2333
Interest expense(185)(402)
Unrealized gain on warrant liability4,2031,687
Total other income (expense), net4,0411,318
Income (loss) before benefit from income taxes1,284(5,390)
Net income (loss) and comprehensive income (loss)$ 1,284$ (5,390)
Net income (loss) per share (basic) (in dollars per share)$ 0.28$ (5.91)
Net income (loss) per share (diluted) (in dollars per share)$ 0.28$ (5.91)
Weighted-average common shares (basic) (in shares)4,631,902912,044
Weighted-average common shares (diluted) (in shares)4,631,902912,044

AGRX Balance Sheet

2024-03-31
Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,615$ 2,557
Accounts receivable, net4,8133,392
Inventory, net3,7482,738
Prepaid expenses and other current assets811843
Total current assets11,9879,530
Property and equipment, net5075
Right of use asset335412
Other non-current assets238238
Total assets12,61010,255
Current liabilities:  
Long-term debt, current portion 1,515
Notes payable, current portion 191
Accounts payable12,6209,574
Accrued expenses8,4439,131
Lease liability, current portion378366
Total current liabilities21,44120,777
Lease liabilities, long-term 100
Warrant liability1,4935,696
Total liabilities22,93426,573
Commitments and contingencies (Note 9)
Stockholders' deficit  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at March 31, 2024 and no shares issued and outstanding at December 31, 2023
Common stock, $0.0001 par value, 300,000,000 shares authorized, 6,856,229 and 2,963,657 issued and outstanding at March 31, 2024 and December 31, 2023, respectively54
Additional paid-in capital411,555406,846
Accumulated deficit(421,884)(423,168)
Total stockholders' deficit(10,324)(16,318)
Total liabilities and stockholders' deficit$ 12,610$ 10,255
AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEagiletherapeutics.com
 INDUSTRYPharmaceuticals
 EMPLOYEES22

Agile Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Agile Therapeutics Inc? What does AGRX stand for in stocks?

AGRX is the stock ticker symbol of Agile Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agile Therapeutics Inc (AGRX)?

As of Fri Jul 19 2024, market cap of Agile Therapeutics Inc is 9.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers. The fair value of Agile Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agile Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agile Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGRX is over valued or under valued. Whether Agile Therapeutics Inc is cheap or expensive depends on the assumptions which impact Agile Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGRX.

What is Agile Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AGRX's PE ratio (Price to Earnings) is -1.26 and Price to Sales (PS) ratio is 0.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agile Therapeutics Inc's stock?

In the past 10 years, Agile Therapeutics Inc has provided -0.602 (multiply by 100 for percentage) rate of return.